1. Home
  2. SHOT vs BNR Comparison

SHOT vs BNR Comparison

Compare SHOT & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHOT
  • BNR
  • Stock Information
  • Founded
  • SHOT 2018
  • BNR 2014
  • Country
  • SHOT United States
  • BNR China
  • Employees
  • SHOT N/A
  • BNR N/A
  • Industry
  • SHOT Biotechnology: Pharmaceutical Preparations
  • BNR Medical Specialities
  • Sector
  • SHOT Health Care
  • BNR Health Care
  • Exchange
  • SHOT Nasdaq
  • BNR Nasdaq
  • Market Cap
  • SHOT 30.4M
  • BNR 38.3M
  • IPO Year
  • SHOT 2020
  • BNR 2020
  • Fundamental
  • Price
  • SHOT $0.49
  • BNR $4.63
  • Analyst Decision
  • SHOT
  • BNR
  • Analyst Count
  • SHOT 0
  • BNR 0
  • Target Price
  • SHOT N/A
  • BNR N/A
  • AVG Volume (30 Days)
  • SHOT 7.0M
  • BNR 20.0K
  • Earning Date
  • SHOT 08-13-2025
  • BNR 08-21-2025
  • Dividend Yield
  • SHOT N/A
  • BNR N/A
  • EPS Growth
  • SHOT N/A
  • BNR N/A
  • EPS
  • SHOT N/A
  • BNR N/A
  • Revenue
  • SHOT $573,336.00
  • BNR $72,112,038.00
  • Revenue This Year
  • SHOT N/A
  • BNR $136.32
  • Revenue Next Year
  • SHOT N/A
  • BNR N/A
  • P/E Ratio
  • SHOT N/A
  • BNR N/A
  • Revenue Growth
  • SHOT 69.32
  • BNR 0.53
  • 52 Week Low
  • SHOT $0.23
  • BNR $2.18
  • 52 Week High
  • SHOT $1.77
  • BNR $7.90
  • Technical
  • Relative Strength Index (RSI)
  • SHOT 54.76
  • BNR 73.56
  • Support Level
  • SHOT $0.35
  • BNR $3.06
  • Resistance Level
  • SHOT $0.48
  • BNR $3.50
  • Average True Range (ATR)
  • SHOT 0.06
  • BNR 0.24
  • MACD
  • SHOT 0.01
  • BNR 0.11
  • Stochastic Oscillator
  • SHOT 46.94
  • BNR 82.64

About SHOT Safety Shot Inc.

Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: